Regardless of the survival rate, it is critical to address the issue of recurring bone cancer treatment. Local and systemic therapy are required for effective treatment, with the former focusing on the removal of primary osteosarcoma and the latter on the elimination of cancer cells throughout the body, usually through chemotherapy.
To improve the patient's chances of recovery, systemic therapy is necessary. To get rid of the tumour, you'll need to use local therapy. Micrometastasis, which is undetected by screening measures, is common in people with recurring malignancies. In this scenario, where patients normally receive chemotherapy before and after surgery, systemic therapy is critical.
A multidisciplinary health care team is required to treat bone tumours using a multimodality approach. A primary care physician, an orthopaedic surgeon with tumour experience, a radiation oncologist, paediatric oncologists, a pathologist, paediatric nurse specialists, rehabilitation specialists, philanthropists, social workers, and others make up this team.
It is critical to assemble a multidisciplinary team to ensure that the patient receives appropriate treatment, supportive care, and rehabilitation that will aid in survival and quality of life.
Local Recurrence Treatment
Only a tiny percentage of patients with recurrent disease have local disease and no signs of metastatic disease. In this instance, surgery or amputation is the initial treatment option. Local radiation is the best option if surgery is not an option.
Chemotherapy research and development
Chemotherapy development has progressed significantly over the last few decades. Clinical trials for the treatment of osteosarcoma following surgery with adjuvant chemotherapy boost the patient's chances of survival. Before surgery, neoadjuvant chemotherapy is used to shrink the tumour.
What are the survival rates?
The survival rate refers to the percentage of patients who live for a set amount of time after being diagnosed with cancer, which is usually 5 years. There are many people who live longer than this, as well as many others who recover. The survival statistics are based on past observations of persons who have experienced the condition.
The kind and grade of cancer, the patient's age, the location and size of the tumour, and the treatment received all influence the prognosis of bone cancer. The 5-year survival rate is estimated to be around 70%.